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Background
Live attenuated simian immunodeficiency virus (SIV) elic-
ited the best protective immunity in rhesus monkeys.
However, this vaccine approach was hindered by safety
concerns that the live attenuated HIV-1 may cause harms
in humans. To overcome this problem, we have devel-
oped a replication defective HIV/SIV pseudotyped with
Vesicular Stomatitis Virus G protein (VSV-G) as an AIDS
vaccine model.
Methods
In the vaccine construct, the polymerase, vif, nef and env
genes of HIV/SIV were truncated. Replication defective
viruses were produced by co-transfecting vaccine con-
structs with constructs encoding functional pol and VSV-G
genes. Rhesus monkeys were immunized with replication-
defective HIV/SIV through subcutaneous and intramuscu-
lar routes and monitored for replication competent virus
(RCV) at weekly intervals in the first month and monthly
in the following year. Sixty-seven weeks after immuniza-
tion, three SIV vaccine immunized animals and two naïve
controls were challenged with SIVmac via IV route. Two
persistent infected monkeys also received therapeutic vac-
cines. Immunological responses were monitored during
vaccination and challenge phases.
Results
No RCV was detected at any time-points during 67 weeks.
Furthermore, no side effect was occurred in all vaccinated
monkeys. After challenging, all immunized animals and
naive controls have positive transient viremia. However,
virus load becomes undetectable in the vaccinated ani-
mals two months after challenge by sensitive co-culture
and PCR as compared to high viral loads in control ani-
mals for over one year. The level of CD4 cells also main-
tains at normal level in all vaccinated animals as
compared to 60% drop in control animal. Viral load was
significant reduced (>100-fold) in two monkeys received
therapeutic vaccines.
Conclusion
The studies indicate that replication-defective HIV/SIV is
safe and elicits long lasting protective immunity in rhesus
monkeys. The protection is correlated to cell-mediated
immune responses. Therefore, replication defective HIV-1
may provide a safe vaccine candidate for human clinical
trials.
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